Nikko Asset Management Americas’s Vir Biotechnology VIR Stock Holding History

Nikko Asset Management Americas’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$17.9K	Buy	+1,753	New	+$16.7K	﹤0.01%	275

Other funds holding VIR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Nikko Asset Management Americas's VIR Position: Q2 2026 in Review

Nikko Asset Management Americas opened a new position in Vir Biotechnology (VIR) in Q2 2026: 1,753 shares worth $17.9K. The stake represents ﹤0.01% of the portfolio and ranks #275 among its holdings.

237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

Nikko Asset Management Americas held 1,753 shares of Vir Biotechnology worth $17.9K as of Q2 2026.
Vir Biotechnology was a new Nikko Asset Management Americas position in Q2 2026.
Vir Biotechnology made up ﹤0.01% of Nikko Asset Management Americas's portfolio in Q2 2026, its #275 holding.
237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Nikko Asset Management Americas's 13F filing for Q2 2026, filed 13 Aug 2026.